These findings are consistent with research that shows ALDH enzymatic activity protecting AML cells from chemotherapy and ALDH1A1 null AML cells susceptible to chemotherapy, while ALDH1A1 null patients belong to the favorable risk group [103,104]. This evidence concerns the gene LDHA and acute myeloid leukemia.